Equities
Health CareMedical Equipment and Services
  • Price (USD)31.23
  • Today's Change0.95 / 3.14%
  • Shares traded3.95m
  • 1 Year change-5.54%
  • Beta0.6084
Data delayed at least 15 minutes, as of Jul 01 2025 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

  • Revenue in USD (TTM)10.77bn
  • Net income in USD-277.00m
  • Incorporated1931
  • Employees38.00k
  • Location
    Baxter International IncOne Baxter ParkwayDEERFIELD 60015United StatesUSA
  • Phone+1 (224) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Masimo Corp1.97bn-276.60m9.12bn3.60k--9.63--4.62-5.17-9.2136.5117.460.75172.426.30548,222.30-10.543.29-13.173.9950.5053.94-14.024.561.622.120.40750.002.2617.43-474.11---6.75--
Henry Schein Inc12.67bn407.00m9.13bn25.00k22.712.7013.100.72083.223.22100.1227.081.234.917.86506,760.003.885.436.389.1931.6030.233.163.980.75256.940.37990.002.714.88-6.25-11.0619.66--
Avantor Inc6.69bn715.60m9.17bn13.50k12.821.508.181.371.051.059.808.950.53295.696.01495,200.005.703.946.624.4833.5633.7610.706.870.75323.950.40240.00-2.642.35121.58--23.59--
Penumbra Inc1.24bn42.23m9.94bn4.50k250.168.18156.688.011.031.0331.3831.350.78161.026.89275,577.802.661.422.951.5866.3763.213.411.963.68--0.0190.0012.8616.89-84.59-21.98-0.853--
Revvity Inc2.77bn296.04m11.40bn11.00k39.941.5115.984.122.422.3522.7063.960.21483.054.59251,806.202.304.312.494.8456.2558.5010.6915.782.9914.590.29326.520.162-0.908657.704.201.274.56
Solventum Corp8.31bn379.00m13.12bn22.00k34.864.0214.221.582.182.1847.6918.850.56834.267.74377,636.402.59--3.05--54.71--4.55--0.85231.930.7081--0.6954---64.41------
Align Technology Inc3.98bn409.56m13.72bn20.95k34.463.6524.473.455.495.4953.4151.940.64954.553.96190,061.706.6813.909.9420.5069.9271.2410.2920.951.08--0.000.003.5410.69-5.32-0.9865-5.04--
Cooper Companies Inc3.99bn414.20m14.20bn16.00k34.501.7118.253.562.062.0619.8641.540.32611.585.43249,262.503.398.723.689.7367.2065.7010.3926.351.236.800.23780.2828.417.9833.34-3.177.59--
Hologic Inc4.03bn556.70m14.52bn7.06k27.513.1417.013.612.372.3717.3120.730.46662.576.24570,083.606.4513.127.2715.2056.4460.8213.8324.752.52110.530.3540.00-0.00253.6673.14--4.30--
Illumina Inc4.34bn-965.00m15.10bn8.97k--6.41--3.48-6.10-6.1027.2314.890.53472.606.36483,500.60-11.90-10.33-14.50-12.1566.3465.65-22.25-25.301.4817.300.4566---2.934.29-5.34---9.34--
Baxter International Inc10.77bn-277.00m15.54bn38.00k--2.1922.041.44-0.5388-1.1021.0313.800.43882.645.04283,447.40-1.09-0.8441-1.37-1.0336.7338.63-2.49-2.031.403.650.5882--2.66-1.31-293.68---8.524.12
West Pharmaceutical Services Inc2.90bn467.20m15.72bn10.60k34.375.8625.645.436.376.3739.4737.370.80214.635.30273,188.7012.5615.6115.0018.7034.5438.0015.6618.842.03--0.071610.20-1.929.48-16.9715.3124.435.84
Zimmer Biomet Holdings Inc7.70bn913.40m18.05bn17.00k20.211.469.362.344.514.5138.0662.630.35290.96225.17452,852.904.192.344.752.6871.0571.1811.887.601.466.460.366537.523.85-0.7725-11.742.05-3.690.00
Waters Corp2.98bn657.02m20.77bn7.60k31.6810.5824.416.9611.0211.0250.0432.980.65562.314.45392,533.3014.4418.4118.0223.4659.2758.7122.0222.811.2813.770.4260.000.06674.22-0.68511.61-2.75--
Data as of Jul 01 2025. Currency figures normalised to Baxter International Inc's reporting currency: US Dollar USD

Institutional shareholders

51.75%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202558.59m11.45%
Dodge & Coxas of 31 Mar 202551.46m10.06%
Pzena Investment Management LLCas of 31 Mar 202536.77m7.19%
BlackRock Fund Advisorsas of 31 Mar 202530.27m5.92%
SSgA Funds Management, Inc.as of 31 Mar 202521.77m4.25%
T. Rowe Price Associates, Inc. (IM)as of 31 Mar 202519.57m3.82%
BlackRock Advisors LLCas of 31 Mar 202516.77m3.28%
Geode Capital Management LLCas of 31 Mar 202512.56m2.45%
Harris Associates LPas of 31 Mar 20259.00m1.76%
Newton Investment Management North America LLCas of 31 Mar 20258.02m1.57%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.